Your one-stop-shop for XDCs

Syngene offers an integrated bioconjugation platform for XDCs, providing end-to-end support from antibody discovery to GMP manufacturing at up to 1 kg scale. Their expertise covers diverse conjugation technologies, payload and linker chemistry, and advanced analytical and bioassay support. Syngene ensures single-source manufacturing of antibodies, peptides, oligonucleotides, payloads, and linkers, minimizing risk and delays.
Plasmid, mRNA, & Viral Vector Manufacturing: Scaling for the Gene Therapy Boom

Explore how plasmid DNA, mRNA CDMO, and viral vector manufacturing are scaling to meet the rising demand of AAV gene therapy and genetic medicines. Read on to know more.
Integrated Innovation Partners: The Strategic Edge in Modern Drug Development
Publication: Pharmaceutical Technology Focus
Beyond timelines: How Syngene redefines customer-centric project management

Customer-centric pharma project management software for CRDMO programs—integrating metrics, feedback, and risk on one platform to deliver with speed and quality.
Translational Research at Syngene: From Discovery to Personalized Medicine

Syngene’s translational research speeds drug discovery and development and enables personalized medicine with robust models and biomarkers. Explore the approach.
Batch Manufacturing vs Continuous Manufacturing with Process Analytical Technology

Batch vs continuous manufacturing explained, how process analytical technology enables control and real-time release testing, and when each mode fits best.
The Critical Role of Analytical Development: Supporting a Program with 70+ Method Validations

See how analytical development scales to 70 plus method validations with phase appropriate, risk based strategy and clean execution. Read the full guide today.
Urban Mental Health: Evidence, Action, and Impact through BUMHI

Explore how the BUMHI initiative advances urban mental health through research, evidence-based action, and community impact to build healthier cities.
Cost of Goods Reduction by Design: Strategies for Early-Phase Process Optimization

Reduce CoG by using design of experiments, quality by design, and smart tech transfer in early development. Practical strategies to cut cost without risk.
Computational toxicology – The new frontier in predictive safety assessment

Peptide synthesis and the hidden complexities of scaling peptide therapeutics, from SPPS to purification, analytics, and cGMP manufacturing. Talk to our team today.